Jon Johnson, MD
Internal Medicine · Stillwater, OKNPI 1598765497
Payments from drug & device makers
Across 181 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$398
- Amgen$372
- Boehringer Ingelheim$244
- Abbott$210
- AstraZeneca$194
- Lilly USA, LLC$172
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,998100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $398 |
| Amgen | 18 | $372 |
| Boehringer Ingelheim | 14 | $244 |
| Abbott | 14 | $210 |
| AstraZeneca | 13 | $194 |
| Lilly USA, LLC | 12 | $172 |
| Johnson & Johnson | 4 | $158 |
| AbbVie | 10 | $148 |
| Otsuka America Pharmaceutical, Inc. | 7 | $142 |
| Vanda Pharmaceuticals Inc. | 6 | $114 |
| Eisai Inc. | 7 | $97 |
| Merck | 6 | $84 |
| Astellas Pharma US Inc | 5 | $68 |
| Radius Health, Inc. | 4 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Novartis | 3 | $51 |
| Amarin Pharma, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Neuronetics, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Dexcom, Inc. | 2 | $24 |
| Pfizer | 2 | $24 |
| Redhill Biopharma Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Medtronic | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Kaleo, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| GSK | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,998 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 103 | $99,663 |
| OzempicSemaglutide | 47 | $50,849 |
| TrulicityDulaglutide | 14 | $28,468 |
| XareltoRivaroxaban | 31 | $27,458 |
| EliquisApixaban | 27 | $26,504 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $23,930 |
| JanuviaSitagliptin Phosphate | 25 | $23,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $21,102 |
| FarxigaDapagliflozin Propanediol | 11 | $14,167 |
| Bydureon BciseExenatide Microspheres | 13 | $10,581 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,538 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,793 |
| Atorvastatin Calcium | 519 | $6,736 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $4,874 |
| Pantoprazole Sodium | 330 | $4,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $244 | $99,663103 claims |
| Novo NordiskOzempic | $398 | $50,84947 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $13 | $38,43255 claims |
| Lilly USA, LLCTrulicity | $172 | $28,46814 claims |
| Johnson & JohnsonXarelto | $158 | $27,45831 claims |
| PfizerEliquis | $24 | $26,50427 claims |
| MerckJanuvia | $84 | $23,57125 claims |
| AstraZenecaFarxiga | $194 | $14,16711 claims |
| AbbVieSynthroid | $148 | $1,79831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Stillwater
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.